Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): A randomised, open-label, phase 3 trial

The Lancet Infectious Diseases

Volumn 15, Issue 4, 2015, Pages 387-396

  Chéret, Antoine ^a,b,c   Nembot, Georges ^d   Mélard, Adeline ^a,f   Lascoux, Caroline ^g   Slama, Laurence ^h   Miailhes, Patrick ⁱ   Yeni, Patrick ^j   Abel, Sylvie ^k   Avettand Fenoel, Véronique ^a,f   Venet, Alain ^e   Chaix, Marie Laure ^a,f   Molina, Jean Michel ^e,g   Katlama, Christine ^l   Goujard, Cécile ^c,d   Tamalet, Catherine ^m   Raffi, François ⁿ   Lafeuillade, Alain ^o   Reynes, Jacques ^p   Ravaux, Isabelle ^m   Hoën, Bruno ^q   Delfraissy, Jean François ^c   Meyer, Laurence ^d   Rouzioux, Christine ^a,f   Tran, Laurent ^r   Bénard, Ingrid ^r   Chaillot, Céline ^r   Corvi, Lynda ^r   Harambure, Theodora ^r   more..

^a Hôpital Necker Enfants Malades   (France)

^b Tourcoing Hospital   (France)

^c BICÊTRE HOSPITAL   (France)

^d CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^e INSERM   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g SAINT LOUIS HOSPITAL   (France)

^h HÔPITAL TENON   (France)

ⁱ CROIX ROUSSE HOSPITAL   (France)

^j BICHAT HOSPITAL   (France)

^k CENTRE HOSPITALIER UNIVERSITAIRE DE FORT DE FRANCE   (France)

^l PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^m TIMONE HOSPITAL   (France)

ⁿ AP HP   (France)

^o Font Pré Hospital   (France)

^p GUI DE CHAULIAC HOSPITAL   (France)

^q Centre Hospitalier Universitaire Pointe a Pitre   (Guadeloupe)

^r NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR; EMTRICITABINE; MARAVIROC; RALTEGRAVIR; RITONAVIR; TENOFOVIR DISOPROXIL; VIRUS RNA; ANTIRETROVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTENSIVE CARE; INTENTION TO TREAT ANALYSIS; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OPEN STUDY; PANCREATITIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 3 CLINICAL TRIAL; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; FRANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; ISOLATION AND PURIFICATION; MIDDLE AGED; MONONUCLEAR CELL; PROCEDURES; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; FRANCE; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84925345301     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)70021-6     Document Type: Article

References (33)

1. Prise en charge médicale des personnes vivant avec le VIH, recommandations du groupe d'experts sous la direction du Pr Philippe Morlat et sous l'égide du CNS et de l'ANRS. Rapport 2013 Ministère des Affaires Sociales et de la Santé, (accessed March 3, 2014). http://www.sante.gouv.fr/IMG/pdf/Rapport_Morlat_2013_Mise_en_ligne.pdf.
2. Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci USA 1998, 95:8869-8873.
3. Roberts L, Passmore JA, Williamson C, et al. Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression. AIDS 2010, 24:819-831.
4. Rouzioux C, Hubert JB, Burgard M, et al. Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. J Infect Dis 2005, 192:46-55.
5. Goujard C, Bonarek M, Meyer L, et al. CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis 2006, 42:709-715.
6. Williams JP, Hurst J, Stohr W, et al. HIV-1 DNA predicts disease progression and post-treatment virological control. Elife 2014, 3:e03821.
7. Hocqueloux L, Avettand-Fenoel V, Jacquot S, et al. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. J Antimicrob Chemother 2013, 68:1169-1178.
8. Jain V, Hartogensis W, Bacchetti P, et al. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis 2013, 208:1202-1211.
9. Ghosn J, Deveau C, Chaix ML, et al. Despite being highly diverse, immunovirological status strongly correlates with clinical symptoms during primary HIV-1 infection: a cross-sectional study based on 674 patients enrolled in the ANRS CO 06 PRIMO cohort. J Antimicrob Chemother 2010, 65:741-748.
10. Bell SK, Little SJ, Rosenberg ES Clinical management of acute HIV infection: best practice remains unknown. J Infect Dis 2010, 202(suppl 2):S278-S288.
11. Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007, 46:125-133.
12. Cooper DA, Heera J, Goodrich J, et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010, 201:803-813.
13. Prise en charge médicale des personnes vivant avec le VIH, recommandations du groupe d'experts sous la direction du Pr Patrick Yeni. Rapport 2010 Ministère de la Santé et des Sports, (accessed March 3, 2014). http://www.sante.gouv.fr/IMG/pdf/Rapport_2010_sur_la_prise_en_charge_medicale_des_personnes_infectees_par_le_VIH_sous_la_direction_du_Pr-_Patrick_Yeni.pdf.
14. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003, 17:1871-1879.
15. Avettand-Fenoel V, Chaix ML, Blanche S, et al. LTR real-time PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01). J Med Virol 2009, 81:217-223.
16. Felsenstein J An alternating least squares approach to inferring phylogenies from pairwise distances. Syst Biol 1997, 46:101-111.
17. ANRS scale to grade the severity of adverse events in adults Agence Nationale de Recherche sur le Sida et les Hépatites Virales, (accessed Feb 6, 2015). http://www.anrs.fr/content/download/2242/12805/file/ANRS-GradeEI-V1-En-2008.pdf.
18. Saez-Cirion A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog 2013, 9:e1003211.
19. Viard JP, Burgard M, Hubert JB, et al. Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. AIDS 2004, 18:45-49.
20. Hoen B, Cooper DA, Lampe FC, et al. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005. Clin Infect Dis 2007, 45:381-390.
21. Fletcher CV, Staskus K, Wietgrefe SW, et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci USA 2014, 111:2307-2312.
22. Murray JM, Emery S, Kelleher AD, et al. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 2007, 21:2315-2321.
23. Koelsch KK, Boesecke C, McBride K, et al. Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir. AIDS 2011, 25:2069-2078.
24. Puertas MC, Massanella M, Llibre JM, et al. Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection. AIDS 2014, 28:325-334.
25. Markowitz M, Evering TH, Garmon D, et al. A randomized open-label study of 3- versus 5-drug combination antiretroviral therapy in newly HIV-1 infected individuals. J Acquir Immune Defic Syndr 2014, 66:140-147.
26. Ananworanich J, Schuetz A, Vandergeeten C, et al. Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One 2012, 7:e33948.
27. Hunt PW, Shulman NS, Hayes TL, et al. The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. Blood 2013, 121:4635-4646.
28. Cuzin L, Trabelsi S, Delobel P, et al. Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study. J Acquir Immune Defic Syndr 2012, 61:557-564.
29. Kramer VG, Schader SM, Oliveira M, et al. Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load. Antimicrob Agents Chemother 2012, 56:4154-4160.
30. Bacchus C, Cheret A, Avettand-Fenoel V, et al. A single HIV-1 cluster and a skewed immune homeostasis drive the early spread of HIV among resting CD4+ cell subsets within one month post-infection. PLoS One 2013, 8:e64219.
31. Klatt NR, Chomont N, Douek DC, Deeks SG Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunol Rev 2013, 254:326-342.
32. Eriksson S, Graf EH, Dahl V, et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog 2013, 9:e1003174.
33. Piketty C, Weiss L, Assoumou L, et al. A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir. J Med Virol 2010, 82:1819-1828.